HC Wainwright Issues Positive Estimate for WVE Earnings

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Equities research analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for WAVE Life Sciences in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.33) per share for the quarter, up from their previous forecast of ($0.35). HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for WAVE Life Sciences’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($1.32) EPS.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The company had revenue of $17.25 million during the quarter, compared to analysts’ expectations of $15.68 million. WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%.

Several other research firms have also recently weighed in on WVE. Wedbush boosted their price target on shares of WAVE Life Sciences from $20.00 to $33.00 and gave the stock an “outperform” rating in a report on Friday, December 12th. Wall Street Zen downgraded WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Morgan Stanley set a $28.00 target price on WAVE Life Sciences in a report on Monday, December 8th. Truist Financial increased their price target on WAVE Life Sciences from $36.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Wednesday, January 21st. Thirteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, WAVE Life Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

WAVE Life Sciences Price Performance

NASDAQ WVE opened at $13.20 on Thursday. The company has a fifty day moving average price of $14.09 and a 200-day moving average price of $10.92. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -10.82 and a beta of -1.77. WAVE Life Sciences has a 1 year low of $5.28 and a 1 year high of $21.73.

Institutional Investors Weigh In On WAVE Life Sciences

Large investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC boosted its stake in shares of WAVE Life Sciences by 736.5% during the 3rd quarter. Voya Investment Management LLC now owns 258,011 shares of the company’s stock worth $1,889,000 after acquiring an additional 227,167 shares during the last quarter. Handelsbanken Fonder AB bought a new position in WAVE Life Sciences in the 2nd quarter worth $330,000. JPMorgan Chase & Co. raised its holdings in WAVE Life Sciences by 33.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,569,015 shares of the company’s stock worth $10,199,000 after purchasing an additional 390,078 shares during the period. Federated Hermes Inc. lifted its position in WAVE Life Sciences by 678,144.7% during the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock valued at $27,455,000 after purchasing an additional 3,750,140 shares in the last quarter. Finally, Schroder Investment Management Group grew its holdings in WAVE Life Sciences by 29.7% during the second quarter. Schroder Investment Management Group now owns 621,378 shares of the company’s stock valued at $4,039,000 after purchasing an additional 142,109 shares during the period. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Insider Activity at WAVE Life Sciences

In related news, major shareholder Plc Gsk purchased 1,470,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the acquisition, the insider owned 18,245,691 shares of the company’s stock, valued at $346,668,129. This trade represents a 8.76% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Paul Bolno sold 10,480 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $140,956.00. Following the transaction, the chief executive officer directly owned 275,520 shares of the company’s stock, valued at approximately $3,705,744. This trade represents a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 948,375 shares of company stock worth $14,112,151 over the last 90 days. Corporate insiders own 23.98% of the company’s stock.

Key Headlines Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Late‑breaking oral acceptance for WVE‑006 (RestorAATion‑2) means new clinical data — including results from the 400 mg multidose cohort and 600 mg single‑dose cohort — will be presented at the ATS international conference, creating a near‑term data catalyst that could materially move the stock if results are viewed favorably. Wave Life Sciences Announces Acceptance of Late‑Breaking Oral Presentation on WVE‑006
• Positive Sentiment: HC Wainwright reiterated a Buy and raised near‑term EPS estimates (Q1–Q4 2026 and FY2026 modestly), and keeps a $30 price target — analyst backing can support the stock and attracts momentum investors. The upgrades signal that at least one sell‑side shop expects improving fundamentals ahead. HC Wainwright research (reported by MarketBeat)
• Positive Sentiment: Media coverage noting HC Wainwright’s Buy rating increases visibility; headline coverage can amplify investor reaction to the upgrades and upcoming ATS presentation. WAVE Life Sciences Earns Buy Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright’s long‑range projections are mixed — they trimmed FY2029 slightly but project a sizable positive swing by FY2030. These longer‑horizon forecasts are highly model‑dependent and may not move the stock much until nearer‑term clinical or commercial proof points arrive. HC Wainwright long‑term estimates (reported by MarketBeat)
• Negative Sentiment: Offsetting the positives, WVE remains unprofitable with recent quarterly EPS misses and negative margins; consensus and company guidance still point to continued losses in FY2026, which keeps valuation risk high if upcoming data or execution disappoints.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.